Literature DB >> 2297630

Is chemotherapy effective in reducing the local failure rate in patients with operable breast cancer?

A U Buzdar1, M D McNeese, G N Hortobagyi, T L Smith, S Kau, G Fraschini, V Hug, N Ellerbroek, F A Holmes, F Ames.   

Abstract

To evaluate the role of chemotherapy in local control of primary breast cancer, the incidence of local failure was evaluated in 768 patients treated with surgery and adjuvant, combination chemotherapy that contained fluorouracil, doxorubicin, and cyclophosphamide (FAC) at our institute between 1974 and 1982. Of these patients, 429 received postoperative irradiation (XRT) before adjuvant therapy. A group of 178 historical control patients had mastectomies and received irradiation after surgery without chemotherapy. The rates of locoregional recurrence alone in the three groups were as follows: FAC, 12%; FAC plus XRT, 5%; and XRT, 10%. The difference in recurrence rates between the FAC group and the FAC plus XRT subgroup was significant (P less than 0.01). Local failure rates were evaluated by stage and nodal status; patients with Stage III disease and those with four or more disease-positive nodes had a higher incidence of local failure than did patients with Stage II disease or those who had one to three positive nodes. Systemic chemotherapy and local therapies resulted in 50% local control at the time of locoregional recurrence in patients treated with FAC, whereas local control was achieved in 18% of patients with local recurrence in the XRT subgroups. Overall life-time local control of disease was similar whether irradiation was administered initially (in the period after operation) or at the time of local recurrence. Irradiation after mastectomy remains an integral part of a combined modality approach in selected groups of patients.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2297630     DOI: 10.1002/1097-0142(19900201)65:3<394::aid-cncr2820650303>3.0.co;2-2

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  8 in total

Review 1.  The significance of a supraclavicular node metastasis in patients with breast cancer. A literature review.

Authors:  J M Debois
Journal:  Strahlenther Onkol       Date:  1997-01       Impact factor: 3.621

2.  Long-term outcomes in patients with isolated supraclavicular nodal recurrence after mastectomy and doxorubicin-based chemotherapy for breast cancer.

Authors:  Jay P Reddy; Larry Levy; Julia L Oh; Eric A Strom; George H Perkins; Thomas A Buchholz; Wendy A Woodward
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-12-16       Impact factor: 7.038

3.  How do I deal with the axilla in patients with a positive sentinel lymph node?

Authors:  Conrad B Falkson
Journal:  Curr Treat Options Oncol       Date:  2011-12

4.  Aggressive therapy for locoregional recurrence after mastectomy in stage II and III breast cancer patients.

Authors:  E M Mora; S E Singletary; A U Buzdar; D A Johnston
Journal:  Ann Surg Oncol       Date:  1996-03       Impact factor: 5.344

Review 5.  Clinical decision-making in early breast cancer.

Authors:  C M Balch; S E Singletary; K I Bland
Journal:  Ann Surg       Date:  1993-03       Impact factor: 12.969

6.  Skin-sparing mastectomy with immediate breast reconstruction: the M. D. Anderson Cancer Center experience.

Authors:  S E Singletary
Journal:  Ann Surg Oncol       Date:  1996-07       Impact factor: 5.344

7.  Incidental irradiation of internal mammary lymph nodes in breast cancer: conventional two-dimensional radiotherapy versus conformal three-dimensional radiotherapy.

Authors:  Elton Trigo Teixeira Leite; Rafael Tsuneki Ugino; Marco Antônio Santana; Denis Vasconcelos Ferreira; Maurício Russo Lopes; Edilson Lopes Pelosi; João Luis Fernandes da Silva; Heloisa de Andrade Carvalho
Journal:  Radiol Bras       Date:  2016 May-Jun

8.  The combination of radiotherapy, adjuvant chemotherapy (cyclophosphamide-doxorubicin-ftorafur) and tamoxifen in stage II breast cancer. Long-term follow-up results of a randomised trial.

Authors:  C Blomqvist; K Tiusanen; I Elomaa; P Rissanen; T Hietanen; E Heinonen; P Gröhn
Journal:  Br J Cancer       Date:  1992-12       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.